Xiamen Bioendo Technology Co., Ltd. was founded in 1978 and has been deeply engaged in the field of endotoxin detection for 48 years, specializing in the R&D, production, and technical services of LAL/TAL reagents and endotoxin testing. The company has overcome multiple key technical bottlenecks, actively participated in the development of national industry standards, and its products have been selected as part of the third batch of national reference standards.

BIOENDO offers a comprehensive range of endotoxin detection solutions, including traditional gel clot and photometric methods, while actively promoting innovative alternative methodologies that do not rely on natural horseshoe crab blood—such as the Recombinant Factor C Fluorometric Assay (rFC), Recombinant Cascade Chromogenic Assay (rCR), and Monocyte Activation Test (MAT). These efforts reflect the company’s commitment to the protection of horseshoe crab resources and the advancement of sustainable development strategies.

The company has been honored with multiple prestigious titles, including National High-Tech Enterprise, Specialized and Sophisticated SME, Xiamen Science and Technology Little Giant Enterprise, and Xiamen Advanced Manufacturing Doubling Plan Enterprise.

BIOENDO has strategically integrated reagents, equipment, software, recombinant products, intelligent automation, and system validation into a comprehensive full-chain solution. By advancing its industrial upgrade toward synthetic biology and artificial intelligence, the company is empowering the high-quality development of China’s pharmaceutical industry with new quality productive forces.